awmsg logo



dabrafenib (Tafinlar®)


Reference No. 1844

Publication date:
27/02/2014


Appraisal information

dabrafenib (Tafinlar®) 50 mg capsule
dabrafenib (Tafinlar®) 75 mg capsule


Company: GlaxoSmithKline
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 26/02/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA321) NICE GUIDANCE ISSUED OCTOBER 2014 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). In the absence of a submission from the holder of the marketing authorisation, dabrafenib (Tafinlar®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Statement of Advice (SOA)
Download